| 毕 云,郭贤利,毛艳阳,王 妮,冯小智.法舒地尔在急性ST段抬高型心肌梗死患者PCI术中疗效及安全性[J].现代生物医学进展英文版,2017,17(16):3114-3117. |
| 法舒地尔在急性ST段抬高型心肌梗死患者PCI术中疗效及安全性 |
| Clinical Effect and Safety of Fasudil in Treatment of STEMI Patients Underwent PCI |
| Received:August 02, 2016 Revised:August 26, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.16.029 |
| 中文关键词: 急性ST段抬高型心肌梗死 经皮冠状动脉介入 法舒地尔 疗效 安全性 |
| 英文关键词: STEMI PCI Fasudil Effect Safety |
| 基金项目:陕西省卫生计生委科研基金项目（2016D075） |
|
| Hits: 373 |
| Download times: 199 |
| 中文摘要: |
| 摘要 目的：探讨法舒地尔在急性ST段抬高型心肌梗死（STEMI）患者经皮冠状动脉介入治疗术（PCI）中的疗效及安全性。方法：选择2014年1月至2016年1月间于我院就诊的急性ST段抬高型心肌梗死患者173例作为研究对象，随机将其分为观察组87例及对照组86例。对照组患者单纯行PCI治疗，观察组患者在PCI治疗过程中加用法舒地尔。对两组患者临床疗效、TIMI血流分级、左心功能指标及生化指标以及心血管不良事件进行考察与比较。结果：观察组患者治疗总有效率为90.80 %，高于对照组的70.93 %，P<0.05。治疗前两组患者TIMI血流分级无显著差别（P>0.05），治疗后两组患者TIMI血流3级患者较治疗前明显增多，且观察组TIMI血流3级患者明显多于对照组（P<0.05）。观察组患者治疗后左心功能指标及生化指标均明显优于对照组（P<0.05）。观察组患者心血管不良事件发生率仅为6.90 %，远远低于对照组的45.35 %，P<0.05。结论：急性ST段抬高性心肌梗死患者在PCI术中使用法舒地尔具有良好的临床疗效及安全性，有利于患者心功能改善，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect and safety of fasudil in the treatment of STEMI patients underwent PCI. Methods: 173 patients with STEMI accepted in our hospital from January 2014 to January 2016 were selected and divided into observation group with 87 cases and control group with 86 cases. The patients in control group underwent PCI, and the patients in observation group underwent PCI combined with fasudil. Then the clinical effect, TIMI level grade, indexes of left heart function and biochemistry and cardiovascular adverse reactions of two groups were compared. Results: The total efficiency of observation group was 90.80 %, which was obviously higher than 70.93 % of control group with statistical significance (P<0.05). The TIMI level grade of two groups before treatment had no difference (P>.05), but the patients with TIMI 3 after treatment of two groups were much more than before, and it was more in the observation group than that of control group (P<0.05). The indexes of left heart function and biochemistry of observation group were all higher than those of control group (P<0.05). The incidence of cardiovascular adverse reaction of observation group was 6.90 %, which was obviously lower than 45.35% of control group with statistically significance (P<0.05). Conclusion: Using fasudil during PCI for patients with STEMI has good effect and safety, which can help improve the heart function, worthy of clinical applications. |
|
View Full Text
View/Add Comment Download reader |
| Close |
